Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study
| Autor: | Peter D. Londborg, Michael R. Liebowitz, Nicholas DeMartinis, Cathryn M. Clary, Rana Fayyad, Ward T. Smith, Karen L. Weihs, Henry Chung |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Generalized anxiety disorder Placebo-controlled study Liebowitz social anxiety scale Personal Satisfaction Placebo Severity of Illness Index Drug Administration Schedule Double-Blind Method Internal medicine Sertraline Surveys and Questionnaires medicine Humans Single-Blind Method Psychiatry Social anxiety Drug Tolerance medicine.disease Diagnostic and Statistical Manual of Mental Disorders Psychiatry and Mental health Tolerability Phobic Disorders Quality of Life Female Psychology Anxiety disorder Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The Journal of clinical psychiatry. 64(7) |
| ISSN: | 0160-6689 |
| Popis: | BACKGROUND Generalized social anxiety disorder is an early onset, highly chronic, frequently disabling disorder with a lifetime prevalence of approximately 13%. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for the treatment of severe generalized social anxiety disorder in adults. METHOD After a 1-week single-blind placebo lead-in period, patients with DSM-IV generalized social phobia were randomly assigned to 12 weeks of double-blind treatment with flexible doses of sertraline (50-200 mg/day) or placebo. Primary efficacy outcomes were the mean change in the Liebowitz Social Anxiety Scale (LSAS) total score and the responder rate for the Clinical Global Impressions-Improvement scale (CGI-I), defined as a CGI-I score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|